Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATCOV: Antiviral Pharmacodynamics in Early Symptomatic COVID-19
NCT05041907Phase 2Recruiting
- Sponsor
- University of Oxford
- Start
- Sep 2021
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 2 trial of nitazoxanide, molnupiravir, hydroxychloroquine, fluoxetine, sotrovimab in coronavirus disease 2019 (COVID-19), sponsored by University of Oxford. Started Sep 2021; status: recruiting.
02
Drugs
nitazoxanidemolnupiravirhydroxychloroquinefluoxetinesotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05041907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05041907.